<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Prolonged survival of patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> after aortic root replacement has led to an increased number of patients with aortic complications beyond the root </plain></SENT>
<SENT sid="1" pm="."><plain>Elective replacement of the aortic root removes the most important predilection site for <z:hpo ids='HP_0002617'>aneurysms</z:hpo>, but the distal aorta remains at risk </plain></SENT>
<SENT sid="2" pm="."><plain>Predictors for aortic growth and adverse events in the distal aorta include aortic diameter, aortic distensiblity, previous aortic root replacement, <z:hpo ids='HP_0000822'>hypertension</z:hpo> and <z:hpo ids='HP_0001659'>aortic regurgitation</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>After <z:hpo ids='HP_0002647'>aortic dissection</z:hpo>, the initial false lumen diameter is an independent predictor for late <z:hpo ids='HP_0002617'>aneurysm</z:hpo> formation </plain></SENT>
<SENT sid="4" pm="."><plain>Although there are a few reports of short-term success after endovascular stent grafting of the descending thoracic aorta, stent grafting in patients with <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e> is not recommended unless intervention is clearly indicated and the risk of conventional open surgical repair is deemed prohibitive </plain></SENT>
<SENT sid="5" pm="."><plain>Optimal long-term outcome demands lifelong radiographic follow-up and medical treatment with beta-blocker therapy </plain></SENT>
<SENT sid="6" pm="."><plain>After <z:hpo ids='HP_0002647'>aortic dissection</z:hpo> rigorous <z:chebi fb="0" ids="35674">antihypertensive</z:chebi> medication is of utmost importance </plain></SENT>
<SENT sid="7" pm="."><plain><z:chebi fb="0" ids="6541">Losartan</z:chebi>, an <z:chebi fb="0" ids="2719,48432">angiotensin II</z:chebi> type I receptor <z:chebi fb="68" ids="48706">antagonist</z:chebi>, might offer the first potential for primary prevention of clinical manifestations in <z:e sem="disease" ids="C0024796" disease_type="Disease or Syndrome" abbrv="MFS|MFS1">Marfan syndrome</z:e>, but the results of clinical trials have to be awaited </plain></SENT>
<SENT sid="8" pm="."><plain>(Neth Heart J 2008;16:382-6.) </plain></SENT>
</text></document>